Key points are not available for this paper at this time.
A traceless site-selective conjugation method, “AJICAP-M,” was developed for native antibodies at specific sites using Fc-affinity peptides, focusing on Lys248 or Lys288. It produces antibody-drug conjugates (ADCs) with consistent drug-to-antibody ratios, enhanced stability, and simplified manufacturing. Comparative in vivo assessment demonstrated AJICAP-M's superior stability over traditional ADCs. This technology has been successfully applied to continuous-flow manufacturing, marking the first achievement in site-specific ADC production. This manuscript outlines AJICAP-M's methodology and its effectiveness in ADC production.
Matsuda et al. (Tue,) studied this question.